Cost effectiveness of palivizumab in Spain: An analysis using observational data

European Journal of Health Economics

Volumn 11, Issue 1, 2010, Pages 105-115

  Nuijten, Mark J ^a,b   Wittenberg, Wolfgang ^c  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b Ars Accessus Medica   (Netherlands)

^c ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Cost effectiveness; Model; Palivizumab; Respiratory syncytial virus; Spain

Indexed keywords

PALIVIZUMAB;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HIGH RISK INFANT; HUMAN; INFANT; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPAIN; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK FACTORS; SPAIN;

EID: 76649093908     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-009-0206-x     Document Type: Article

References (31)

1. EA Simoes 1999 Respiratory syncytial virus infection Lancet 354 9181 847 852 10.1016/S0140-6736(99)80040-3 (Pubitemid 29415599)
2. SD Canfield EA Simoes 1999 Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab Pediatr. Ann. 28 8 507 514
3. S Clark M Beresford N Subhedar N Shaw 2000 Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort Arch. Dis. Child. 83 313 316 10.1136/adc.83.4.313 (Pubitemid 30744771)
4. JR Groothuis EA Simoes MJ Levin, et al. 1993 Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group N. Engl. J. Med. 329 1524 1530 10.1056/NEJM199311183292102 (Pubitemid 23332437)
5. The PREVENT Study Group 1997 Reduction of RSV hospitalisation among preterm infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis Pediatrics 99 93 99 10.1542/peds.99.1.93 (Pubitemid 27136610)
6. The IMpact Study Group 1998 Palivizumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high risk infants Pediatrics 102 531 537 10.1542/peds.102.3.531 (Pubitemid 28409250)
7. X Carbonell Estrany J Quero Jimenez 2000 Comité de Estándares de la Sociedad Española de Neonatología, y Junta Directiva de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por virus respiratorio sincitial An Esp Pediatr 52 4 372 374
8. N Sigurs R Bjarnason F Sigurbergsson B Kjellman 2000 Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7 Am. J. Respir. Crit. Care Med. 161 5 1501 1507
9. JS Sampalis 2003 Morbidity and mortality after RSV-associated hospitalisations among premature Canadian infants J. Pediatr. 143 5 Suppl S150 S156
10. S Joffe GT Ray GJ Escobar SB Black TA Lieu 1999 Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants Pediatrics 104 3 Pt 1 419 427 10.1542/peds.104.3.419 (Pubitemid 29424659)
11. The European Medicines Agency: http://www.emea.eu.int/index/indexh1.htm, accessed December 2007
12. TF Feltes AK Cabalka HC Meissner, et al. 2003 Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease J. Pediatr. 143 532 540 10.1067/S0022-3476(03)00454-2 (Pubitemid 37352516)
13. L Bont W van Aalderen J Kimpen 2000 Long term consequences of respiratory syncytial virus (RSV) bronchiolitis Paediatr. Respir. Rev. 1 221 227 10.1053/prrv.2000.0052
14. N Sigurs R Bjarnason F Sigurbergsson B Kjellman B Bjorksten 1995 Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls Pediatrics 95 500 505
15. EAF Simoes X Carbonell-Estrany J Kimpen CHL Rieger DD Morris PF Pollack JR Groothuis 2004 Palavizumab use decreases risk of recurrent wheezing in preterm children Eur. Respir. J. 24 Suppl 48 212s
16. MJ Nuijten W Wittenberg M Lebmeier 2007 Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis Pharmacoeconomics 25 1 55 71 10.2165/00019053-200725010-00006
17. P Lázaro y de Mercado J Figueras Aloy E Domenech Martinez, et al. 2006 The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain An Pediatr (Barc) 65 4 316 324 10.1157/13092505 (Pubitemid 44860162)
18. C Pedraz X Carbonell-Estrany J Figueras-Aloy J Quero IRIS Study Group 2003 Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalisations in premature infants Pediatr. Infect. Dis. J. 22 9 823 827 10.1097/01.inf.0000086403.50417.7c (Pubitemid 37153079)
19. MJC Nuijten 1998 Data management in modelling studies: the selection of data sources Pharmacoeconomics 3 3 305 316 10.2165/00019053-199813030-00005 (Pubitemid 28123370)
20. JL Pinto-Prades V Ortún-Rubio J Puig-Junoy 2001 El análisis coste-efectividad en sanidad Aten Primaria 27 275 278
21. ®) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. A West Midlands Development and Evaluation Service Report Department of Public Health & Epidemiology. University of Birmingham Edgbaston, Birmingham B15 2TT. ISBN No. 0704423219 Copyright, West Midlands Health Technology Assessment Group Department of Public Health and Epidemiology. University of Birmingham (2001)
22. Instituto Nacional de Estadística (INE).: Datos demográficos básicos, esperanza de vida al nacimiento. Disponible en: http://www.ine.es/(consultado en septiembre de 2005)
23. A Greenough J Alexander S Burgess, et al. 2004 Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection Arch. Dis. Child. 89 673 678 10.1136/adc.2003.036129
24. Personal communication with Dr P Lázaro y de Mercado: Técnicas Avanzadas de Invetigatión en Servicios de Salud, April 2007
25. Retribuciones del personal sanitario.: Generalitat de Valencia. Available at http://www.dival.es. (Accessed August 2005)
26. X Carbonell-Estrany J Quero G Bustos A Cotero E Domenech J Figueras-Aloy JM Fraga LG Garcia A Garcia-Alix MG Del Rio X Krauel JB Sastre E Narbona V Roques SS Hernandez M Zapatero 2000 Rehospitalisation because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group Pediatr. Infect. Dis. J. 19 7 592 597 10.1097/00006454-200007000-00002 (Pubitemid 30469763)
27. Orden 234/2005, de 23 de febrero, del Consejero de Sanidad y Consumo, por la que sefijan los precios públicos por la prestación de los servicios y actividades de naturaleza sanitaria de la Red de Centros de la Comunidad de Madrid. Boletín Oficial de la Comunidad de Madrid (BOCM) núm. 56, 8 de Marzo de, 2005
28. L Bont WM Aalderen JL Kimpen 2000 Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis Paediatr. Respir. Rev. 1 3 221 227 10.1053/prrv.2000.0052
29. A Greenough S Cox J Alexander, et al. 2004 Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection Arch. Dis. Child. 85 6 463 468 10.1136/adc.85.6.463
30. Instituto Nacional de Estadística (INE).: Contabilidad Regional de España. Available at http://ine.es. (Consulted in January 2006)
31. F Laufer 2005 Thresholds in cost-effectiveness analysis-more of the story Value Health 8 1 86 87 10.1111/j.1524-4733.2005.08103.x (Pubitemid 40293647)